Exalenz Bioscience has announced positive trial data that reveals its BreathID breath test system and 13C-di-peptide substrate could be used to diagnose chronic pancreatitis.
The study, which included 33 subjects, compared the accuracy of the 13C-di-peptide breath test to the endoscopic pancreatic function test, and also measured the ability of the breath test to differentiate between healthy subjects and those with chronic pancreatitis.
The findings from the study concluded that a 13C-di-peptide breath test using the BreathID system can non-invasively diagnose chronic pancreatitis with good accuracy.
Related
Related Companies
